Cargando…

Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload

AIMS: Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan in a pressure overload model of heart failure with pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordén, Einar Sjaastad, Bendiksen, Bård Andre, Andresen, Henriette, Bergo, Kaja Knudsen, Espe, Emil Knut, Hasic, Almira, Hauge‐Iversen, Ida Marie, Veras, Ioanni, Hussain, Rizwan I., Sjaastad, Ivar, Christensen, Geir, Cataliotti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006657/
https://www.ncbi.nlm.nih.gov/pubmed/33497525
http://dx.doi.org/10.1002/ehf2.13177
_version_ 1783672349266018304
author Nordén, Einar Sjaastad
Bendiksen, Bård Andre
Andresen, Henriette
Bergo, Kaja Knudsen
Espe, Emil Knut
Hasic, Almira
Hauge‐Iversen, Ida Marie
Veras, Ioanni
Hussain, Rizwan I.
Sjaastad, Ivar
Christensen, Geir
Cataliotti, Alessandro
author_facet Nordén, Einar Sjaastad
Bendiksen, Bård Andre
Andresen, Henriette
Bergo, Kaja Knudsen
Espe, Emil Knut
Hasic, Almira
Hauge‐Iversen, Ida Marie
Veras, Ioanni
Hussain, Rizwan I.
Sjaastad, Ivar
Christensen, Geir
Cataliotti, Alessandro
author_sort Nordén, Einar Sjaastad
collection PubMed
description AIMS: Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan in a pressure overload model of heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: Sprague–Dawley rats underwent aortic banding or sham (n = 16) surgery and were randomized to sac/val (n = 28), valsartan (n = 29), or vehicle (n = 26) treatment for 8 weeks. Sac/val reduced left ventricular weight by 11% compared with vehicle (P = 0.01) and 9% compared with valsartan alone (P = 0.04). Only valsartan reduced blood pressure compared with sham (P = 0.02). Longitudinal early diastolic strain rate was preserved in sac/val compared with sham, while it was reduced by 23% in vehicle (P = 0.03) and 24% in valsartan (P = 0.02). Diastolic dysfunction, measured by E/e'SR, increased by 68% in vehicle (P < 0.01) and 80% in valsartan alone (P < 0.001), while sac/val showed no increase. Neither sac/val nor valsartan prevented interstitial fibrosis. Although ejection fraction was preserved, we observed mild systolic dysfunction, with vehicle showing a 28% decrease in longitudinal strain (P < 0.01). Neither sac/val nor valsartan treatment improved this dysfunction. CONCLUSIONS: In a model of HFpEF induced by cardiac pressure overload, sac/val reduced hypertrophy compared with valsartan alone and ameliorated diastolic dysfunction. These effects were independent of blood pressure. Early systolic dysfunction was not affected, supporting the notion that sac/val has the largest potential in conditions characterized by reduced ejection fraction. Observed anti‐hypertrophic effects in preserved ejection fraction implicate potential benefit of sac/val in the clinical setting of hypertrophic remodelling and impaired diastolic function.
format Online
Article
Text
id pubmed-8006657
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-80066572021-04-01 Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload Nordén, Einar Sjaastad Bendiksen, Bård Andre Andresen, Henriette Bergo, Kaja Knudsen Espe, Emil Knut Hasic, Almira Hauge‐Iversen, Ida Marie Veras, Ioanni Hussain, Rizwan I. Sjaastad, Ivar Christensen, Geir Cataliotti, Alessandro ESC Heart Fail Original Research Articles AIMS: Sacubitril/valsartan (sac/val) has shown superior effect compared with blockade of the renin–angiotensin–aldosterone system in heart failure with reduced ejection fraction. We aimed to investigate effects of sac/val compared with valsartan in a pressure overload model of heart failure with preserved ejection fraction (HFpEF). METHODS AND RESULTS: Sprague–Dawley rats underwent aortic banding or sham (n = 16) surgery and were randomized to sac/val (n = 28), valsartan (n = 29), or vehicle (n = 26) treatment for 8 weeks. Sac/val reduced left ventricular weight by 11% compared with vehicle (P = 0.01) and 9% compared with valsartan alone (P = 0.04). Only valsartan reduced blood pressure compared with sham (P = 0.02). Longitudinal early diastolic strain rate was preserved in sac/val compared with sham, while it was reduced by 23% in vehicle (P = 0.03) and 24% in valsartan (P = 0.02). Diastolic dysfunction, measured by E/e'SR, increased by 68% in vehicle (P < 0.01) and 80% in valsartan alone (P < 0.001), while sac/val showed no increase. Neither sac/val nor valsartan prevented interstitial fibrosis. Although ejection fraction was preserved, we observed mild systolic dysfunction, with vehicle showing a 28% decrease in longitudinal strain (P < 0.01). Neither sac/val nor valsartan treatment improved this dysfunction. CONCLUSIONS: In a model of HFpEF induced by cardiac pressure overload, sac/val reduced hypertrophy compared with valsartan alone and ameliorated diastolic dysfunction. These effects were independent of blood pressure. Early systolic dysfunction was not affected, supporting the notion that sac/val has the largest potential in conditions characterized by reduced ejection fraction. Observed anti‐hypertrophic effects in preserved ejection fraction implicate potential benefit of sac/val in the clinical setting of hypertrophic remodelling and impaired diastolic function. John Wiley and Sons Inc. 2021-01-26 /pmc/articles/PMC8006657/ /pubmed/33497525 http://dx.doi.org/10.1002/ehf2.13177 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Research Articles
Nordén, Einar Sjaastad
Bendiksen, Bård Andre
Andresen, Henriette
Bergo, Kaja Knudsen
Espe, Emil Knut
Hasic, Almira
Hauge‐Iversen, Ida Marie
Veras, Ioanni
Hussain, Rizwan I.
Sjaastad, Ivar
Christensen, Geir
Cataliotti, Alessandro
Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title_full Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title_fullStr Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title_full_unstemmed Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title_short Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
title_sort sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006657/
https://www.ncbi.nlm.nih.gov/pubmed/33497525
http://dx.doi.org/10.1002/ehf2.13177
work_keys_str_mv AT nordeneinarsjaastad sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT bendiksenbardandre sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT andresenhenriette sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT bergokajaknudsen sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT espeemilknut sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT hasicalmira sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT haugeiversenidamarie sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT verasioanni sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT hussainrizwani sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT sjaastadivar sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT christensengeir sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload
AT cataliottialessandro sacubitrilvalsartanamelioratescardiachypertrophyandpreservesdiastolicfunctionincardiacpressureoverload